Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.

Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H.

Sci Transl Med. 2019 May 1;11(490). pii: eaao5563. doi: 10.1126/scitranslmed.aao5563.

PMID:
31043571
2.

IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.

Yshii L, Pignolet B, Mauré E, Pierau M, Brunner-Weinzierl M, Hartley O, Bauer J, Liblau R.

JCI Insight. 2019 Apr 4;4(7). pii: 127001. doi: 10.1172/jci.insight.127001. eCollection 2019 Apr 4.

3.

Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.

Bernard-Valnet R, Pignolet B, Biotti D, Ciron J, Lafontan JF, Dumas H, Bonneville F, Brassat D.

Mult Scler Relat Disord. 2018 Oct;25:216-218. doi: 10.1016/j.msard.2018.08.006. Epub 2018 Aug 7.

PMID:
30114625
4.

Reply.

Fissolo N, Pignolet B, Brassat D, Comabella M.

Ann Neurol. 2017 Oct;82(4):647-648. doi: 10.1002/ana.25039. Epub 2017 Oct 4. No abstract available.

PMID:
28869673
5.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
6.

CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model.

Gebauer C, Pignolet B, Yshii L, Mauré E, Bauer J, Liblau R.

Oncoimmunology. 2016 Dec 9;6(2):e1260212. doi: 10.1080/2162402X.2016.1260212. eCollection 2017.

7.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
8.

CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice.

Bernard-Valnet R, Yshii L, Quériault C, Nguyen XH, Arthaud S, Rodrigues M, Canivet A, Morel AL, Matthys A, Bauer J, Pignolet B, Dauvilliers Y, Peyron C, Liblau RS.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10956-61. doi: 10.1073/pnas.1603325113. Epub 2016 Sep 12.

9.

CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.

Yshii LM, Gebauer CM, Pignolet B, Mauré E, Quériault C, Pierau M, Saito H, Suzuki N, Brunner-Weinzierl M, Bauer J, Liblau R.

Brain. 2016 Nov 1;139(11):2923-2934. doi: 10.1093/brain/aww225.

PMID:
27604307
10.

Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.

Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D; on behalf SFSEP, BIONAT Network; RISC.

J Neurol Sci. 2016 Sep 15;368:334-6. doi: 10.1016/j.jns.2016.07.052. Epub 2016 Jul 25.

PMID:
27538659
11.

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.

Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, Brassat D, Wiendl H.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e195. doi: 10.1212/NXI.0000000000000195. eCollection 2016 Feb.

12.

PML risk stratification using anti-JCV antibody index and L-selectin.

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.

Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2.

PMID:
26432858
13.

Migration of encephalitogenic CD8 T cells into the central nervous system is dependent on the α4β1-integrin.

Martin-Blondel G, Pignolet B, Tietz S, Yshii L, Gebauer C, Perinat T, Van Weddingen I, Blatti C, Engelhardt B, Liblau R.

Eur J Immunol. 2015 Dec;45(12):3302-12. doi: 10.1002/eji.201545632. Epub 2015 Oct 6.

14.

[Migration and pathogenicity of CD8 T cells in central nervous system diseases].

Martin-Blondel G, Pignolet B, Liblau RS.

Med Sci (Paris). 2015 Aug-Sep;31(8-9):748-55. doi: 10.1051/medsci/20153108013. Epub 2015 Sep 4. Review. French.

15.

Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.

Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.

Mult Scler. 2015 Apr;21(5):671-2. doi: 10.1177/1352458514549823. Epub 2014 Oct 10. No abstract available.

PMID:
25305251
16.
17.

EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation.

Lazarczyk M, Dalard C, Hayder M, Dupre L, Pignolet B, Majewski S, Vuillier F, Favre M, Liblau RS.

PLoS One. 2012;7(6):e39995. doi: 10.1371/journal.pone.0039995. Epub 2012 Jun 28.

18.

Cutting edge: neuronal recognition by CD8 T cells elicits central diabetes insipidus.

Scheikl T, Pignolet B, Dalard C, Desbois S, Raison D, Yamazaki M, Saoudi A, Bauer J, Lassmann H, Hardin-Pouzet H, Liblau RS.

J Immunol. 2012 May 15;188(10):4731-5. doi: 10.4049/jimmunol.1102998. Epub 2012 Apr 13.

19.

Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.

Top S, Foulon E, Pignolet B, Deplanche M, Caubet C, Tasca C, Bertagnoli S, Meyer G, Foucras G.

J Virol. 2011 Dec;85(24):12982-94. doi: 10.1128/JVI.00128-11. Epub 2011 Aug 10.

20.

Transgenic mouse models of multiple sclerosis.

Scheikl T, Pignolet B, Mars LT, Liblau RS.

Cell Mol Life Sci. 2010 Dec;67(23):4011-34. doi: 10.1007/s00018-010-0481-9. Epub 2010 Aug 17. Review.

PMID:
20714779
21.

Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants.

Pignolet B, Boullier S, Gelfi J, Bozzetti M, Russo P, Foulon E, Meyer G, Delverdier M, Foucras G, Bertagnoli S.

J Gen Virol. 2008 Jun;89(Pt 6):1371-9. doi: 10.1099/vir.0.83595-0.

PMID:
18474552
22.

In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains.

Pignolet B, Duteyrat JL, Allemandou A, Gelfi J, Foucras G, Bertagnoli S.

Virol J. 2007 Sep 27;4:94.

23.

A virulence factor of myxoma virus colocalizes with NF-kappaB in the nucleus and interferes with inflammation.

Camus-Bouclainville C, Fiette L, Bouchiha S, Pignolet B, Counor D, Filipe C, Gelfi J, Messud-Petit F.

J Virol. 2004 Mar;78(5):2510-6.

Supplemental Content

Loading ...
Support Center